The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Effective Post-Exposure Treatment of Ebola Infection
Open accessAbstract
Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an increasing re-emergence in Central Africa and a potential for use as a biological weapon. There is no vaccine or treatment licensed for human use. In the past, however, important advances have been made in developing preventive vaccines that are protective in animal models. In this regard, we showed that a single injection of a live-attenuated recombinant vesicular stomatitis virus vector expressing the Ebola virus glycoprotein completely protected rodents and nonhuman primates from lethal Ebola challenge. In contrast, progress in developing therapeutic interventions against Ebola virus infections has been much slower and there is clearly an urgent need to develop effective post-exposure strategies to respond to future outbreaks and acts of bioterrorism, as well as to treat laboratory exposures. Here we tested the efficacy of the vesicular stomatitis virus-based Ebola vaccine vector in post-exposure treatment in three relevant animal models. In the guinea pig and mouse models it was possible to protect 50% and 100% of the animals, respectively, following treatment as late as 24 h after lethal challenge. More important, four out of eight rhesus macaques were protected if treated 20 to 30 min following an otherwise uniformly lethal infection. Currently, this approach provides the most effective post-exposure treatment strategy for Ebola infections and is particularly suited for use in accidentally exposed individuals and in the control of secondary transmission during naturally occurring outbreaks or deliberate release.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Jones, S. M., Feldmann, H., Ströher, U., Geisbert, J. B., Fernando, L., Grolla, A., Klenk, H.-D., Sullivan, N. J., Volchkov, V. E., Fritz, E. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1258 · Cited by 687
Self-citationCatastrophic ape decline in western equatorial Africa
Walsh, P. D., Abernethy, K. A., Bermejo, M., Beyers, R., De Wachter, P., Akou, M. E., Huijbregts, B., Mambounga, D. I., Toham, A. K., Kilbourn, A. M., et al. (2003) · Nature · doi:10.1038/nature01566 · Cited by 681
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques
Geisbert, T. W., Hensley, L. E., Larsen, T., Young, H. A., Reed, D. S., Geisbert, J. B., Scott, D. P., Kagan, E., Jahrling, P. B., & Davis, K. J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63591-2 · Cited by 576
Self-citationRupprecht, C. E., Hanlon, C. A., & Hemachudha, T. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00287-6 · Cited by 575
A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic Fever
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., & Huggins, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/515386 · Cited by 492
Self-citationThe Ebola virus VP35 protein functions as a type I IFN antagonist
Basler, C. F., Wang, X., Mühlberger, E., Volchkov, V., Paragas, J., Klenk, H.-D., García-Sastre, A., & Palese, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.220398297 · Cited by 478
The Ebola Virus VP35 Protein Inhibits Activation of Interferon Regulatory Factor 3
Basler, C. F., Mikulasova, A., Martinez-Sobrido, L., Paragas, J., Mühlberger, E., Bray, M., Klenk, H.-D., Palese, P., & García-Sastre, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7945-7956.2003 · Cited by 477
Self-citationEbola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation
Reid, S. P., Leung, L. W., Hartman, A. L., Martinez, O., Shaw, M. L., Carbonnelle, C., Volchkov, V. E., Nichol, S. T., & Basler, C. F. (2006) · Journal of Virology · doi:10.1128/jvi.02349-05 · Cited by 463
Cited by
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Self-citationHenao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., Carroll, M. W., Dean, N. E., Diatta, I., Doumbia, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32621-6 · Cited by 1,110
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Self-citationOestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Self-citationA Recombinant Vesicular Stomatitis Virus Ebola Vaccine
Regules, J. A., Beigel, J. H., Paolino, K. M., Voell, J., Castellano, A. R., Hu, Z., Muñoz, P., Moon, J. E., Ruck, R. C., Bennett, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1414216 · Cited by 387
Olinger, G. G., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S. D., Johnson, A. K., Morton, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213709109 · Cited by 366
Self-citationSuccessful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies
Qiu, X., Audet, J., Wong, G., Pillet, S., Bello, A., Cabral, T., Strong, J. E., Plummer, F., Corbett, C. R., Alimonti, J. B., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003876 · Cited by 315
Geisbert, T. W., Geisbert, J. B., Leung, A., Daddario-DiCaprio, K. M., Hensley, L. E., Grolla, A., & Feldmann, H. (2009) · Journal of Virology · doi:10.1128/jvi.00561-09 · Cited by 275
Self-citationPostexposure antibody prophylaxis protects nonhuman primates from filovirus disease
Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200409109 · Cited by 268
Metadata
- Authors
- Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., Bray, M., Fritz, E. A., Fernando, L., Feldmann, F., Hensley, L. E., & Geisbert, T. W.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007
- Volume
- 3
- Issue
- 1
- Pages
- e2
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2050813818
- Cited by
- 288
- References
- 35
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.